Dopamine receptor pharmacology.
Identifieur interne : 002457 ( Ncbi/Merge ); précédent : 002456; suivant : 002458Dopamine receptor pharmacology.
Auteurs : P. Seeman [Canada] ; H H Van TolSource :
- Current opinion in neurology and neurosurgery [ 0951-7383 ] ; 1993.
English descriptors
- KwdEn :
- Animals, Antiparkinson Agents (pharmacology), Antipsychotic Agents (pharmacology), Brain (drug effects), Brain (physiopathology), Clozapine (pharmacology), Humans, Parkinson Disease (physiopathology), Receptors, Dopamine (drug effects), Receptors, Dopamine (physiology), Receptors, Dopamine D1 (drug effects), Receptors, Dopamine D1 (physiology), Receptors, Dopamine D2 (drug effects), Receptors, Dopamine D2 (physiology), Schizophrenia (physiopathology).
- MESH :
- chemical , drug effects : Receptors, Dopamine, Receptors, Dopamine D1, Receptors, Dopamine D2.
- chemical , pharmacology : Antiparkinson Agents, Antipsychotic Agents, Clozapine.
- drug effects : Brain.
- chemical , physiology : Receptors, Dopamine, Receptors, Dopamine D1, Receptors, Dopamine D2.
- physiopathology : Brain, Parkinson Disease, Schizophrenia.
- Animals, Humans.
Abstract
Although antipsychotic drugs originally helped to discover dopamine receptors, the five dopamine receptors presently identified and cloned are facilitating the search for and discovery of more selective antipsychotic and antiparkinson drugs. The D1-like dopamine receptors, D1 and D5, are sensitive to the same drugs as the D1 receptor in native tissues, but D5 is about 10 times more sensitive to dopamine than D1. The D2-like receptors, D2, D3, and D4, have approximately similar sensitivities to dopamine, but bromocriptine and raclopride are both about two orders of magnitude weaker at D4, whereas clozapine is one order more potent at D4, as compared with D2 and D3. The human dopamine D4 receptor has many variants. The sensitivities to clozapine of human variants D4.2, D4.4, and D4.7 are approximately similar, with dissociation constants between 5 and 24 nM, matching the spinal fluid concentration of clozapine under therapeutic conditions. Thus antipsychotic action may be effected through blockade of either dopamine D2 or D4 receptors.
PubMed: 8104554
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001A04
- to stream PubMed, to step Curation: 001A04
- to stream PubMed, to step Checkpoint: 001A04
Links to Exploration step
pubmed:8104554Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine receptor pharmacology.</title><author><name sortKey="Seeman, P" sort="Seeman, P" uniqKey="Seeman P" first="P" last="Seeman">P. Seeman</name><affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacology, University of Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology, University of Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Van Tol, H H" sort="Van Tol, H H" uniqKey="Van Tol H" first="H H" last="Van Tol">H H Van Tol</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1993">1993</date><idno type="RBID">pubmed:8104554</idno><idno type="pmid">8104554</idno><idno type="wicri:Area/PubMed/Corpus">001A04</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001A04</idno><idno type="wicri:Area/PubMed/Curation">001A04</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001A04</idno><idno type="wicri:Area/PubMed/Checkpoint">001A04</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001A04</idno><idno type="wicri:Area/Ncbi/Merge">002457</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Dopamine receptor pharmacology.</title><author><name sortKey="Seeman, P" sort="Seeman, P" uniqKey="Seeman P" first="P" last="Seeman">P. Seeman</name><affiliation wicri:level="4"><nlm:affiliation>Department of Pharmacology, University of Toronto, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Pharmacology, University of Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author><author><name sortKey="Van Tol, H H" sort="Van Tol, H H" uniqKey="Van Tol H" first="H H" last="Van Tol">H H Van Tol</name></author></analytic><series><title level="j">Current opinion in neurology and neurosurgery</title><idno type="ISSN">0951-7383</idno><imprint><date when="1993" type="published">1993</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiparkinson Agents (pharmacology)</term><term>Antipsychotic Agents (pharmacology)</term><term>Brain (drug effects)</term><term>Brain (physiopathology)</term><term>Clozapine (pharmacology)</term><term>Humans</term><term>Parkinson Disease (physiopathology)</term><term>Receptors, Dopamine (drug effects)</term><term>Receptors, Dopamine (physiology)</term><term>Receptors, Dopamine D1 (drug effects)</term><term>Receptors, Dopamine D1 (physiology)</term><term>Receptors, Dopamine D2 (drug effects)</term><term>Receptors, Dopamine D2 (physiology)</term><term>Schizophrenia (physiopathology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Dopamine</term><term>Receptors, Dopamine D1</term><term>Receptors, Dopamine D2</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Antipsychotic Agents</term><term>Clozapine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Dopamine</term><term>Receptors, Dopamine D1</term><term>Receptors, Dopamine D2</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term><term>Parkinson Disease</term><term>Schizophrenia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although antipsychotic drugs originally helped to discover dopamine receptors, the five dopamine receptors presently identified and cloned are facilitating the search for and discovery of more selective antipsychotic and antiparkinson drugs. The D1-like dopamine receptors, D1 and D5, are sensitive to the same drugs as the D1 receptor in native tissues, but D5 is about 10 times more sensitive to dopamine than D1. The D2-like receptors, D2, D3, and D4, have approximately similar sensitivities to dopamine, but bromocriptine and raclopride are both about two orders of magnitude weaker at D4, whereas clozapine is one order more potent at D4, as compared with D2 and D3. The human dopamine D4 receptor has many variants. The sensitivities to clozapine of human variants D4.2, D4.4, and D4.7 are approximately similar, with dissociation constants between 5 and 24 nM, matching the spinal fluid concentration of clozapine under therapeutic conditions. Thus antipsychotic action may be effected through blockade of either dopamine D2 or D4 receptors.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8104554</PMID><DateCreated><Year>1993</Year><Month>11</Month><Day>05</Day></DateCreated><DateCompleted><Year>1993</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0951-7383</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>4</Issue><PubDate><Year>1993</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Current opinion in neurology and neurosurgery</Title><ISOAbbreviation>Curr Opin Neurol Neurosurg</ISOAbbreviation></Journal><ArticleTitle>Dopamine receptor pharmacology.</ArticleTitle><Pagination><MedlinePgn>602-8</MedlinePgn></Pagination><Abstract><AbstractText>Although antipsychotic drugs originally helped to discover dopamine receptors, the five dopamine receptors presently identified and cloned are facilitating the search for and discovery of more selective antipsychotic and antiparkinson drugs. The D1-like dopamine receptors, D1 and D5, are sensitive to the same drugs as the D1 receptor in native tissues, but D5 is about 10 times more sensitive to dopamine than D1. The D2-like receptors, D2, D3, and D4, have approximately similar sensitivities to dopamine, but bromocriptine and raclopride are both about two orders of magnitude weaker at D4, whereas clozapine is one order more potent at D4, as compared with D2 and D3. The human dopamine D4 receptor has many variants. The sensitivities to clozapine of human variants D4.2, D4.4, and D4.7 are approximately similar, with dissociation constants between 5 and 24 nM, matching the spinal fluid concentration of clozapine under therapeutic conditions. Thus antipsychotic action may be effected through blockade of either dopamine D2 or D4 receptors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seeman</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, University of Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Tol</LastName><ForeName>H H</ForeName><Initials>HH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Neurol Neurosurg</MedlineTA><NlmUniqueID>8809879</NlmUniqueID><ISSNLinking>0951-7383</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011954">Receptors, Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017447">Receptors, Dopamine D1</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011954" MajorTopicYN="N">Receptors, Dopamine</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017447" MajorTopicYN="N">Receptors, Dopamine D1</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017448" MajorTopicYN="N">Receptors, Dopamine D2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>46</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8104554</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Ontario</li></region><settlement><li>Toronto</li></settlement><orgName><li>Université de Toronto</li></orgName></list><tree><noCountry><name sortKey="Van Tol, H H" sort="Van Tol, H H" uniqKey="Van Tol H" first="H H" last="Van Tol">H H Van Tol</name></noCountry><country name="Canada"><region name="Ontario"><name sortKey="Seeman, P" sort="Seeman, P" uniqKey="Seeman P" first="P" last="Seeman">P. Seeman</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002457 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002457 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:8104554
|texte= Dopamine receptor pharmacology.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:8104554" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |